{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:08:49Z","timestamp":1788768529734,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,10,9]],"date-time":"2006-10-09T00:00:00Z","timestamp":1160352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2006,10,9]],"date-time":"2006-10-09T00:00:00Z","timestamp":1160352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      To investigate the utility of an individualized chemo\/immunotherapy regimen of intravesical therapy based on the results of an assessment of\n                      <jats:italic>in vitro<\/jats:italic>\n                      cytotoxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      Intravesical adjuvant chemo\/immunotherapy was given to 47 patients based on the results of\n                      <jats:italic>in vitro<\/jats:italic>\n                      cytotoxicity assay of the responses of cultured autologous tumour cells to various cytotoxic drugs (mitomycin\u2010C, doxorubicin and cisplatin) and immunomodulating agents (bacillus Calmette\u2013Gu\u00e9rin, BCG and interferon\u2010\u03b12b). Intravesical therapy was given as single\u2010 or double\u2010drug regimens according to the assay results: 16 (34%) patients showed cytotoxicity to a single drug and 31 (66%) showed maximum cytotoxicity to a combination of immunomodulators and cytotoxic agents. The efficacy of treatment in terms of tumour\u2010free survival and recurrence rate was compared with 40 patients receiving intravesical BCG according to International Protocol (control group).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      In the\n                      <jats:italic>in vitro<\/jats:italic>\n                      assay group, seven patients (15%) had tumour recurrence, compared to 15 (38%) in the control group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.02). In the\n                      <jats:italic>in vitro<\/jats:italic>\n                      group, one of 16 patients on a single drug and six on the double\u2010drug regimen had a recurrence. The patients given BCG with cytotoxic drugs had no recurrences, but 29% of patients given interferon\u2010\u03b12b combinations had recurrences. Kaplan\u2013Meier analysis showed a longer recurrence\u2010free survival in the\n                      <jats:italic>in vitro<\/jats:italic>\n                      group (75%) than in the control group (49%) at 48\u2003months of follow\u2010up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      Intravesical therapy based on an\n                      <jats:italic>in vitro<\/jats:italic>\n                      cytotoxicity assay is an attempt to give individualized therapy, and to increase tumour\u2010free survival in these patients, with no side\u2010effects. Recurrences in seven patients in the\n                      <jats:italic>in vitro<\/jats:italic>\n                      group might be due to a defective host immune response, or to expansion of a subclone of tumour cells resistant to all treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2006.06482.x","type":"journal-article","created":{"date-parts":[[2006,10,9]],"date-time":"2006-10-09T04:37:31Z","timestamp":1160368651000},"page":"1012-1017","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant intravesical therapy based on an\n                    <i>in vitro<\/i>\n                    cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder"],"prefix":"10.1111","volume":"98","author":[{"given":"Sunita","family":"Saxena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhilasha","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandagudi Srinivasa","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayan Kumar","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,9]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.49.1.8"},{"key":"e_1_2_7_3_2","first-page":"39","article-title":"Intravesical therapy: does it affect the natural history of superficial bladder cancer","volume":"10","author":"Lamm DL","year":"1992","journal-title":"Semin Urol"},{"key":"e_1_2_7_4_2","first-page":"394","volume-title":"Comprehensive Textbook of Genitourinary Oncology.","author":"Vogelzang NJ","year":"2000"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)49877-6"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00041-F"},{"key":"e_1_2_7_7_2","first-page":"502","volume-title":"J Urol","author":"Martinez\u2010Pineiro JA","year":"1990"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050448"},{"key":"e_1_2_7_9_2","first-page":"455","article-title":"Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients","volume":"21","author":"Agiostratidou G","year":"2001","journal-title":"Anticancer Res"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00256892"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199812000-00001"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose\u2013response of bacillus Calmette\u2010Guerin in the treatment of superficial bladder cancer","volume":"147","author":"Morales A","year":"1992","journal-title":"J Urol"},{"key":"e_1_2_7_15_2","first-page":"253","volume-title":"BCG in Superficial Bladder Cancer","author":"Pagano F","year":"1989"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07422-4"},{"key":"e_1_2_7_17_2","first-page":"488","article-title":"Recent knowledge on BCG\u2019s mechanism of action in the treatment of superficial bladder cancer","volume":"26","author":"B\u00f6hle A","year":"2000","journal-title":"Braz J Urol"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.545"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.1996.tb00490.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-5347(17)36577-1","article-title":"Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of an European Organisation for Research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group","volume":"148","author":"Bouffioux C","year":"1992","journal-title":"J Urol"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36198-0"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686952"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65757-6"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39547-2"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.3.6.809"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42445-1"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2005.37.1.44"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68935-5"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.8.597"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830160709"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050244"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2006.06482.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2006.06482.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1464-410X.2006.06482.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2006.06482.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:25:52Z","timestamp":1788765952000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2006.06482.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1111\/j.1464-410X.2006.06482.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2006.06482.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,9]]},"assertion":[{"value":"2006-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}